Related Experiment Video
Updated: May 7, 2026
Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System
Published on: February 10, 2023
Sonodynamic antitumor effect of a novel sonosensitizer on S180 solid tumor
Purpose:
The purpose of this study was to evaluate the sonodynamically induced antitumor effect of a novel sonosensitizer (DVDMS) in mice bearing sarcoma 180 solid tumors.
Methods:
In order to determine the optimum timing of ultrasound exposure after administration of DVDMS, a three-dimensional optical imaging system (IVIS spectrum) was used to observe the biodistribution of DVDMS in S180 tumor. The antitumor effects were estimated by the tumor inhibition ratio (volume and weight) after sonodynamic therapy.
Results:
The experiments suggested that DVDMS has a preferential localization in tumors, but a low accumulation in most normal tissues. A significant synergistic effect of ultrasound combined with DVDMS was obtained when the load power indicated 4 W and DVDMS dose was above 2 mg/kg. At day 14 after DVDMS-SDT, the tumor volume inhibition ratio was 56.27%. In addition, the tumor weight inhibition ratio after the synergistic treatment was 55.37%, which was obviously stronger than ultrasound treatment alone (23.85%) and DVDMS alone (23.15%). Moreover, no metastasis occurred to the tumors in the SDT-treated mice compared with the control group.
Conclusions:
DVDMS is a potential sensitizer for sonodynamic cancer therapy. The antitumor effect of ultrasound could be enhanced in the presence of DVDMS, which might be involved in a sonochemical mechanism.
Insights
This study shows that DVDMS enhances ultrasound's antitumor effects in sarcoma 180 tumors. Sonodynamic therapy with DVDMS significantly inhibited tumor growth and prevented metastasis in mice.
Area of Science:
- Biomedical Engineering
- Oncology
- Photodynamic Therapy
Background:
- Sonodynamic therapy (SDT) offers a non-invasive approach for cancer treatment.
- Novel sonosensitizers are crucial for enhancing SDT efficacy.
- Sarcoma 180 solid tumors in mice serve as a model for evaluating new cancer therapies.
Purpose of the Study:
- To evaluate the antitumor effect of a novel sonosensitizer, DVDMS, in combination with ultrasound.
- To determine the optimal conditions for DVDMS-mediated sonodynamic therapy.
- To assess the biodistribution and tumor-specific accumulation of DVDMS.
Main Methods:
- Utilized a three-dimensional optical imaging system (IVIS spectrum) to track DVDMS biodistribution in sarcoma 180 tumors.
- Administered varying doses of DVDMS and applied ultrasound at different power levels.
- Quantified antitumor effects by measuring tumor volume and weight inhibition ratios post-therapy.
Main Results:
- DVDMS demonstrated preferential accumulation in tumors with minimal uptake in normal tissues.
- Optimal synergistic effects were achieved with a DVDMS dose above 2 mg/kg and 4 W ultrasound power.
- DVDMS-based SDT resulted in significant tumor volume (56.27%) and weight (55.37%) inhibition, outperforming ultrasound or DVDMS alone.
- No metastasis was observed in the SDT-treated group, unlike the control group.
Conclusions:
- DVDMS is a promising sonosensitizer for enhancing sonodynamic cancer therapy.
- The combination of DVDMS and ultrasound exhibits potent antitumor activity.
- The enhanced efficacy may be attributed to a sonochemical mechanism, warranting further investigation.
